NPI: 1518033349 · SAN FRANCISCO, CA 94110 · Urgent Care Clinic/Center · NPI assigned 11/24/2006
Authorized official ARNOLD, TIMOTHY controls 20+ related entities in our dataset. Read more
| Authorized Official | ARNOLD, TIMOTHY (DEPUTY DIRECTOR, PFS) |
| NPI Enumeration Date | 11/24/2006 |
Other providers sharing the same authorized official: ARNOLD, TIMOTHY
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 10,503 | $3.09M |
| 2019 | 19,736 | $3.32M |
| 2020 | 26,546 | $3.21M |
| 2021 | 39,078 | $4.38M |
| 2022 | 34,164 | $4.01M |
| 2023 | 41,591 | $5.01M |
| 2024 | 37,606 | $4.81M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| T1015 | Clinic visit/encounter, all-inclusive | 82,761 | 81,592 | $27.53M |
| G0467 | Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit | 3,922 | 3,553 | $289K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 34,585 | 34,264 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1,344 | 1,343 | $0.00 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1,159 | 1,157 | $0.00 |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4,006 | 3,980 | $0.00 |
| 87086 | Culture, bacterial; quantitative colony count, urine | 173 | 173 | $0.00 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3,138 | 2,863 | $0.00 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 169 | 169 | $0.00 |
| Z7610 | 1,197 | 859 | $0.00 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 114 | 114 | $0.00 |
| 90656 | 41 | 41 | $0.00 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 96 | 96 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 179 | 179 | $0.00 |
| 87340 | 24 | 24 | $0.00 | |
| 87088 | 173 | 173 | $0.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 24 | 24 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 13 | 13 | $0.00 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 28 | 28 | $0.00 |
| 86803 | 25 | 25 | $0.00 | |
| 87081 | 15 | 15 | $0.00 | |
| 87430 | 28 | 28 | $0.00 | |
| 86780 | 30 | 29 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 15 | 15 | $0.00 |
| Z7500 | 63,764 | 62,937 | $0.00 | |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 409 | 409 | $0.00 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 4,770 | 4,706 | $0.00 |
| 99201 | 192 | 192 | $0.00 | |
| 81002 | 2,831 | 2,812 | $0.00 | |
| 81025 | 503 | 502 | $0.00 | |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 3,234 | 3,233 | $0.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 205 | 203 | $0.00 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 27 | 27 | $0.00 |
| 99215 | Prolong outpt/office vis | 30 | 30 | $0.00 |